JP2017532961A - Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 - Google Patents

Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 Download PDF

Info

Publication number
JP2017532961A
JP2017532961A JP2017520449A JP2017520449A JP2017532961A JP 2017532961 A JP2017532961 A JP 2017532961A JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017532961 A JP2017532961 A JP 2017532961A
Authority
JP
Japan
Prior art keywords
smad7
day
antisense oligonucleotide
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017520449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532961A5 (enExample
Inventor
ジョヴァニ モンテレオーネ，
ジョヴァニ モンテレオーネ，
Original Assignee
ノグラ ファーマ リミテッド
ノグラ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノグラ ファーマ リミテッド, ノグラ ファーマ リミテッド filed Critical ノグラ ファーマ リミテッド
Publication of JP2017532961A publication Critical patent/JP2017532961A/ja
Publication of JP2017532961A5 publication Critical patent/JP2017532961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017520449A 2014-10-17 2015-10-16 Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 Pending JP2017532961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
US62/065,598 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (2)

Publication Number Publication Date
JP2017532961A true JP2017532961A (ja) 2017-11-09
JP2017532961A5 JP2017532961A5 (enExample) 2018-11-29

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520449A Pending JP2017532961A (ja) 2014-10-17 2015-10-16 Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物

Country Status (12)

Country Link
US (2) US10337004B2 (enExample)
EP (1) EP3207136A1 (enExample)
JP (1) JP2017532961A (enExample)
KR (1) KR20170069262A (enExample)
CN (1) CN107406851A (enExample)
AU (1) AU2015332624A1 (enExample)
CA (1) CA2964667A1 (enExample)
EA (1) EA201790867A1 (enExample)
IL (1) IL251717A0 (enExample)
MA (1) MA43331A (enExample)
MX (1) MX2017004973A (enExample)
WO (1) WO2016059239A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
AU2012307336B2 (en) 2011-09-15 2017-08-24 Nogra Pharma Limited Methods for monitoring responsiveness to anti-SMAD7 therapy
CA2870547A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MA39963A (fr) 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
JP2017537973A (ja) * 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
JP2017532961A (ja) 2014-10-17 2017-11-09 ノグラ ファーマ リミテッド Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物
EP3420082A4 (en) * 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
EP3562943A1 (en) * 2016-12-30 2019-11-06 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
MX2022013261A (es) * 2020-04-24 2022-11-14 Nogra Pharma Ltd Composiciones de oligonucleotidos antisentido (aso) contra smad7 y metodos para usar las mismas.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521815A (ja) * 2003-04-02 2006-09-28 ジュリアーニ インターナショナル リミテッド Ｓｍａｄ７に対するアンチセンスオリゴヌクレオチド（ＯＤＮ）及びその医療分野での使用
JP2012515547A (ja) * 2009-01-26 2012-07-12 アカデミス ズィーケンハイス レイデン ハー．オー．デー．エン． エルユーエムセー Ｎｏｔｃｈ３タンパク質発現および／またはｎｏｔｃｈ３のコード領域を調節するための手段および方法；ｃａｄａｓｉｌの処置におけるその組成物および使用
JP2013518605A (ja) * 2010-02-08 2013-05-23 アイシス ファーマシューティカルズ， インコーポレーテッド 対立遺伝子多様体の選択的低減

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
AU2012307336B2 (en) 2011-09-15 2017-08-24 Nogra Pharma Limited Methods for monitoring responsiveness to anti-SMAD7 therapy
CA2870547A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
WO2014140333A1 (en) 2013-03-15 2014-09-18 Nogra Pharma Limited Methods of treating colorectal cancer
MA39963A (fr) * 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
EP3207135A2 (en) 2014-10-17 2017-08-23 Celgene Alpine Investment Company II, LLC Isotopologues of smad7 antisense oligonucleotides
JP2017532961A (ja) 2014-10-17 2017-11-09 ノグラ ファーマ リミテッド Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
US20180289692A1 (en) 2015-09-30 2018-10-11 Celgene Corporation Tlr modulators and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521815A (ja) * 2003-04-02 2006-09-28 ジュリアーニ インターナショナル リミテッド Ｓｍａｄ７に対するアンチセンスオリゴヌクレオチド（ＯＤＮ）及びその医療分野での使用
JP2012515547A (ja) * 2009-01-26 2012-07-12 アカデミス ズィーケンハイス レイデン ハー．オー．デー．エン． エルユーエムセー Ｎｏｔｃｈ３タンパク質発現および／またはｎｏｔｃｈ３のコード領域を調節するための手段および方法；ｃａｄａｓｉｌの処置におけるその組成物および使用
JP2013518605A (ja) * 2010-02-08 2013-05-23 アイシス ファーマシューティカルズ， インコーポレーテッド 対立遺伝子多様体の選択的低減

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Submitted SNP(ss) Details: ss1361057160", NCBI DBSNP SHORT GENETIC VARIATIONS, vol. Submitter SNP ID PHASE3_V1_74691084, JPN6019029910, 16 August 2014 (2014-08-16), pages 144204026, ISSN: 0004270597 *

Also Published As

Publication number Publication date
MX2017004973A (es) 2017-12-07
IL251717A0 (en) 2017-06-29
AU2015332624A1 (en) 2017-05-04
KR20170069262A (ko) 2017-06-20
MA43331A (fr) 2017-08-23
EP3207136A1 (en) 2017-08-23
CA2964667A1 (en) 2016-04-21
US20190338283A1 (en) 2019-11-07
CN107406851A (zh) 2017-11-28
US10337004B2 (en) 2019-07-02
EA201790867A1 (ru) 2017-08-31
US20170240893A1 (en) 2017-08-24
WO2016059239A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
US10337004B2 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
JP5727484B2 (ja) Ｉ型インターフェロン診断法
US9279158B2 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
US20200032264A1 (en) Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
Fury et al. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance
CN112368301B (zh) 用于选择和治疗炎性疾病患者的方法和系统
Bogaert et al. Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease
CN107530431B (zh) 生物标志物
US20200103418A1 (en) Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
JP2017515896A (ja) 炎症性腸疾患の処置の方法
US20240034799A1 (en) Methods and systems of stratifying inflammatory disease patients
WO2017055611A2 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
US20210207143A1 (en) Methods of Treating Celiac Disease Using SMAD7 Inhibition
KR20180028524A (ko) Fgfr 발현 및 fgfr 억제제에 대한 민감성
WO2018025923A1 (ja) 抗ｈｔｌｖ－１剤、ｈｔｌｖ－１関連脊髄症（ｈａｍ／ｔｓｐ）治療薬
US11162097B2 (en) Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2021250546A1 (en) Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
US20180136226A1 (en) Method for diagnosing an inflammatory disorder
JP2012080777A (ja) ネフローゼ症候群の検査方法、並びにネフローゼ症候群の予防又は治療薬およびそのスクリーニング方法
HK40059533A (en) Methods, systems, and kits for treating inflammatory disease targeting il18r1
KR101082138B1 (ko) 아스피린 과민성 천식 진단용 ｉｌ17ｒａ 유전자 다형성 마커

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200529